Hospital
Logan Memorial Hospital LLC
Logan Memorial Hospital LLC was paid $14.29M by Medicaid between Jan 2018 and Jun 2024, across 151 billing codes. Its largest line is 99283, emergency room visit (moderate) — 16% of everything it billed.
33Billing provider infoLOGAN MEMORIAL HOSPITAL LLC
RUSSELLVILLE, KY 42276
RUSSELLVILLE, KY 42276
33aNPI1992893416assigned 10/10/2006
33bProvider typeRural Acute Care Hospital
28Total paid$14.29M
24GClaims290,923
24DCodes billed151
24AFirst – last monthJan 2018 – Jun 2024
Compared with peers
Next to other Rural Acute Care Hospital providers in Kentucky
Rank by total paid#9 of 10
Median peer was paid$23.35M
This provider vs. median0.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official TRAYLOR, JOHNETTA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 48,169 | $2.62M | |
| 2019 | 47,053 | $2.30M | |
| 2020 | 38,777 | $1.97M | |
| 2021 | 46,056 | $2.14M | |
| 2022 | 43,056 | $2.09M | |
| 2023 | 46,351 | $2.18M | |
| 2024incomplete | 21,461 | $996K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 18,270 | 14,943 | $2.23M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 9,946 | 8,002 | $2.11M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 13% | 2,677 | 1,963 | $1.79M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 7.1% | 2,000 | 1,567 | $1.01M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.4% | 2,966 | 2,223 | $920K |
| 70450 | Computed tomography, head or brain; without contrast material | 5.1% | 3,211 | 2,196 | $725K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.4% | 5,539 | 4,872 | $489K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.0% | 7,417 | 2,555 | $289K |
| 71046 | Radiologic examination, chest; 2 views | 2.0% | 4,794 | 3,483 | $283K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 2,793 | 1,630 | $262K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.8% | 849 | 702 | $254K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.6% | 8,038 | 5,315 | $222K |
139 more codes
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.3% | 4,828 | $180K |
| 71045 | Radiologic examination, chest; single view | 1.3% | 5,113 | $179K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.2% | 4,572 | $169K |
| 80053 | Comprehensive metabolic panel | 1.1% | 22,427 | $159K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.0% | 18,472 | $148K |
| 71250 | <1% | 693 | $129K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,351 | $125K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 795 | $121K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,493 | $98K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,611 | $92K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,739 | $90K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,481 | $87K |
| 72100 | <1% | 838 | $81K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,181 | $80K |
| 73562 | <1% | 1,183 | $77K | |
| 73630 | <1% | 946 | $69K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,783 | $69K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,803 | $69K |
| 81001 | <1% | 9,098 | $68K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,753 | $65K |
| 73610 | <1% | 954 | $64K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 10,447 | $63K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,602 | $58K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,155 | $57K |
| 36415 | Collection of venous blood by venipuncture | <1% | 18,569 | $53K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,260 | $51K |
| 87400 | <1% | 2,499 | $50K | |
| 73030 | <1% | 638 | $48K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,501 | $47K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,445 | $45K |
| 80061 | Lipid panel | <1% | 4,470 | $44K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 876 | $43K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 660 | $42K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,249 | $41K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,479 | $40K |
| 84484 | <1% | 3,761 | $35K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,589 | $34K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,214 | $33K |
| 76830 | Ultrasound, transvaginal | <1% | 168 | $31K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,383 | $30K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,076 | $30K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 959 | $29K |
| 83690 | <1% | 4,040 | $28K | |
| 73130 | <1% | 335 | $24K | |
| 82150 | <1% | 3,214 | $23K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,394 | $22K |
| 83735 | <1% | 4,132 | $19K | |
| 87186 | <1% | 2,154 | $19K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,640 | $19K |
| 85730 | <1% | 2,176 | $19K | |
| 82607 | <1% | 1,545 | $19K | |
| 87077 | <1% | 3,907 | $18K | |
| 93975 | <1% | 224 | $17K | |
| 81025 | <1% | 1,848 | $16K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 980 | $15K |
| 82746 | <1% | 1,084 | $13K | |
| 87430 | <1% | 913 | $13K | |
| 80076 | <1% | 1,325 | $12K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 860 | $12K |
| 74018 | <1% | 158 | $11K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 907 | $11K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,038 | $11K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,330 | $11K |
| 85610 | <1% | 2,944 | $11K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 931 | $11K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 128 | $10K |
| 83880 | <1% | 471 | $9K | |
| 73110 | <1% | 135 | $9K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 84 | $9K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 874 | $9K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 43 | $9K |
| 87070 | <1% | 1,268 | $8K | |
| 97161 | <1% | 165 | $8K | |
| 82728 | <1% | 858 | $8K | |
| 83605 | <1% | 1,074 | $7K | |
| 72131 | <1% | 20 | $7K | |
| 84439 | <1% | 918 | $7K | |
| 84703 | <1% | 743 | $6K | |
| 93971 | <1% | 64 | $5K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 43 | $5K |
| 73502 | <1% | 72 | $5K | |
| 86140 | <1% | 1,414 | $5K | |
| 87040 | <1% | 387 | $5K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 12 | $5K |
| 87081 | <1% | 847 | $4K | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 606 | $4K |
| 70486 | <1% | 15 | $4K | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 272 | $4K |
| 84436 | <1% | 674 | $4K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 23 | $3K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 121 | $3K |
| 84479 | <1% | 611 | $3K | |
| 72040 | <1% | 36 | $3K | |
| 83550 | <1% | 427 | $3K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 92 | $3K |
| 83540 | <1% | 535 | $3K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 37 | $3K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 92 | $3K |
| 85379 | <1% | 370 | $3K | |
| 82962 | <1% | 735 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 95 | $2K |
| 12001 | <1% | 31 | $2K | |
| 76536 | <1% | 16 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 86 | $2K |
| 76642 | <1% | 31 | $2K | |
| 86171 | <1% | 162 | $1K | |
| 97162 | <1% | 13 | $1K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 33 | $1K |
| J3490 | Unclassified drugs | <1% | 404 | $925.91 |
| 36600 | <1% | 149 | $825.57 | |
| 94060 | <1% | 14 | $815.27 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 24 | $651.72 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 18 | $492.35 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 17 | $452.53 |
| 82043 | <1% | 75 | $423.35 | |
| 82670 | <1% | 17 | $405.39 | |
| 82248 | <1% | 37 | $361.07 | |
| 84145 | <1% | 13 | $345.91 | |
| 83615 | <1% | 76 | $305.61 | |
| 82550 | <1% | 61 | $291.28 | |
| 0012A | <1% | 26 | $269.11 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 18 | $253.04 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 14 | $229.01 |
| J0595 | Injection, butorphanol tartrate, 1 mg | <1% | 12 | $193.98 |
| 85652 | <1% | 96 | $176.84 | |
| 0011A | <1% | 26 | $175.16 | |
| 83001 | <1% | 16 | $164.59 | |
| 83002 | <1% | 16 | $164.08 | |
| 82570 | <1% | 51 | $145.65 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 18 | $133.85 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 97 | $92.86 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 15 | $89.23 |
| 82542 | <1% | 15 | $83.42 | |
| 86900 | <1% | 29 | $58.40 | |
| 86901 | <1% | 29 | $58.40 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 12 | $39.80 |
| 86592 | <1% | 14 | $31.24 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 37 | $0.02 |
| 91301 | 0% | 51 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTRAYLOR, JOHNETTA (AO)
| Provider | Location | Paid |
|---|---|---|
| Logan General Hospital LLC | Logan, WV | $43.43M |
| Phc-Cleveland LLC | Cleveland, MS | $23.43M |
| Hartsville, LLC | Hartsville, SC | $18.42M |
| Southwestern Medical Center, LLC | Lawton, OK | $9.40M |
| Palestine Principal Healthcare Limited Partnership | Palestine, TX | $6.80M |
| Watertown Medical Center LLC | Watertown, WI | $6.31M |
| Amg - Livingston, LLC | Livingston, TN | $5.52M |
| Logan General Hospital LLC | Logan, WV | $4.91M |
| ST. Joseph Hospital LLC | Lewiston, ID | $4.67M |
| Riverton Memorial Hospital LLC | Riverton, WY | $4.65M |
| Livingston Regional Hospital LLC | Livingston, TN | $4.33M |
| Hartsville Medical Group LLC | Hartsville, SC | $4.16M |
| Mexia Principal Healthcare Limited Partnership | Mexia, TX | $2.19M |
| Palestine Principal Healthcare Limited Partnership | Palestine, TX | $1.27M |
| Texas Specialty Physicians | Palestine, TX | $1.26M |
| ST Joseph Hospital LLC | Lewiston, ID | $1.10M |
| Watertown Physician Practices LLC | Watertown, WI | $244K |
| Watertown Physician Practices LLC | Watertown, WI | $175K |
| Amg-Livingston LLC | Livingston, TN | $165K |
| Watertown Physician Practices LLC | Watertown, WI | $149K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.